# cell therapy

USC researchers engineered granulocyte-monocyte progenitors, an immature immune-cell type.
The cells expanded in the laboratory and generated new immune cells after establishing in mouse bone marrow.
In mice, the approach slowed blood cancers and solid tumors; human clinical effectiveness remains unproven.

DT Editorial Team·Oct 16, 2026·via sciencedaily.com

In Vivo BCMA CAR-T Shows Limited Durability in Myeloma Follow-Up

Nature Medicine published an extended follow-up of four patients with relapsed or refractory multiple myeloma treated with in vivo BCMA CAR-T cells.
The reported outcome indicates limited duration of response among the four participants.
In vivo CAR-T generates engineered T cells inside the patient rather than through external manufacturing, potentially reducing cost and turnaround time.
BCMA is a validated target on myeloma plasma cells, but durability remains the central unresolved question for the approach.

DT Editorial Team·Oct 6, 2026·via nature.com

Induced pluripotent stem cell technology: a decade of progress | Nature Reviews Drug Discovery (via www.nature.com)

Induced pluripotent stem cells move toward standardized medicine

A Nature Medicine review says iPSC science has matured into a clinical platform with trials and early approvals underway.
The field’s progress rests on advances in nonintegrating reprogramming, differentiation, tissue engineering and genome editing.
Researchers still face major barriers in biological variability, manufacturing complexity and long-term safety surveillance.
The authors argue automation and AI could help turn iPSC workflows into scalable, standardized biological medicine systems.

DT Editorial Team·Aug 31, 2026·via nature.com

$Nature Medicine on X: "In a phase 1 trial, #CD19 #CART treatment of patients with severe, treatment-refractory #RheumatoidArthritis was mostly safe with clinical improvement seen in all patients. https://t.co/QY60Z3cV4s" / X (via x.com)$

Phase 1 CAR-T trial points to a new path for severe rheumatoid arthritis

Nature Medicine published phase 1 results from the ongoing COMPARE trial on August 27, 2026.
Six patients with severe, treatment-refractory, ACPA-positive rheumatoid arthritis received a single infusion of miv-cel.
The study evaluates an autologous fully human CD19 CAR-T therapy aimed at B-cell depletion in autoimmune disease.

DT Editorial Team·Aug 31, 2026·via nature.com

CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings (via www.mdpi.com)

CAR-T cells tracked a decade after lymphoma treatment

A Nature Medicine report says CD19 CAR T cells were detectable at least 10 years after treatment.
The finding comes from analysis of longitudinal blood samples in patients with B cell lymphomas.
The result strengthens the case that some CAR T therapies can persist as long-lived living medicines.

DT Editorial Team·Aug 10, 2026·via nature.com

A renewable cell source for cancer immunotherapy could make off-the-shelf treatments possible

USC team reports renewable cell source for macrophage cancer therapies

USC-led researchers reported a way to extensively expand granulocyte-monocyte progenitors in the lab.
The progenitor cells can be engineered to target cancer markers and support broader immune responses.
The work suggests a scalable starting point for macrophage-based, potentially off-the-shelf cell therapies.

DT Editorial Team·Jun 19, 2026·via medicalxpress.com

Engineered stem cells reverse new-onset type 1 diabetes in mice

A MUSC team reported reversal of new-onset type 1 diabetes in mice.
The cells were engineered to withstand inflammation better than standard MSCs.
Human translation remains uncertain but the mechanism is clinically relevant.

DT Editorial Team·Jun 7, 2026·via medicalxpress.com

Macrophage cell therapy boosts four-year transplant-free survival in advanced cirrhosis

Macrophage Cell Therapy Shows Long-Term Promise in Advanced Cirrhosis

A MATCH clinical trial compared macrophage cell therapy with standard care in advanced cirrhosis.
After four years, 70% of treated patients were alive without transplant versus 40% in the control group.
Researchers reported no serious side effects in treated patients.

DT Editorial Team·May 25, 2026·via medicalxpress.com

CAR T’s biggest weak point may be the patient’s own aging immune cells

Rutgers researchers linked CAR T underperformance to senescent CD8+ T cells used as starting material.
Higher senescence burdens reduced cell expansion under standard CAR T culture conditions.
Analysis of published lymphoma data found stronger senescence signatures were associated with higher failure risk.
The work suggests pre-manufacturing cell-quality screening could improve patient selection and product design.

DT Editorial Team·Apr 30, 2026·via medicalxpress.com

Experimental red-blood-cell delivery system turns immune cells into cancer fighters inside the body

Researchers used engineered red blood cells to carry mRNA-loaded lipid nanoparticles.
The genetic payload is designed to reprogram myeloid immune cells into tumor-targeting cells inside the body.
The strategy could eventually reduce the time and cost associated with conventional CAR cell manufacturing.

DT Editorial Team·Apr 29, 2026·via medicalxpress.com

A CAR-T result in high-risk smoldering multiple myeloma points to a more aggressive early-treatment debate

Medical Xpress reports that a single infusion of ciltacabtagene autoleucel led to a 100% MRD-negativity rate in the studied group.
The reported patients had high-risk smoldering multiple myeloma.
The short source text does not include study size, durability, or safety details, leaving key questions open.

DT Editorial Team·Apr 20, 2026·via medicalxpress.com

Early liver transplant trial hints at a future with less lifelong immunosuppression

Researchers infused donor-derived immune cells before living donor liver transplantation.
Some recipients have stayed off immunosuppressive drugs for more than three years.
The early trial supports larger studies aimed at transplant tolerance.

DT Editorial Team·Apr 17, 2026·via medicalxpress.com

Stem Cell-Derived Insulin Cells Reverse Diabetes in Mice, Advancing Type 1 Therapy

Researchers say they can more reliably produce insulin-secreting cells from human stem cells.
The cells responded to glucose in lab tests and restored blood sugar control in diabetic mice.
The work targets a major hurdle in cell replacement therapy: making mature, pure cell populations.

DT Editorial Team·Apr 16, 2026·via medicalxpress.com

A bold new plan could finally cure type 1 diabetes

Science

Two-Part Cell Therapy Aims to Cure Type 1 Diabetes